ImmunoPharma AS
ImmunoPharma AS is a privately-held, 12-person Norwegian research company that targets immune stimulating substances and operates as an integrated health solutions provider through partnerships with Eqology, NHL Select (Nordic), MycotechPharma, and Smartfish.
- Company typePrivate
- Founded-
- HeadquartersOslo, Norway
- Headcount11–50
- GTM typeB2B
- OfferingServices
What ImmunoPharma AS does
ImmunoPharma AS is a privately-held Norwegian company (Aksjeselskap) headquartered at Mustads vei 1A, 0283 Oslo, with a 12-person team. The company describes itself as a research-based firm targeting immune stimulating substances and positions as an integrated health solutions provider. No specific named products, formulations, delivery mechanisms, clinical-stage assets, or distinct service lines are disclosed on the company website or in the available material; the stated value proposition is functionally "immune health solutions through innovative research," with the competitive advantage described in general terms rather than tied to a concrete technology platform.
The commercial model appears to be defined primarily by a partnership-driven ecosystem rather than vertical integration. The website prominently displays four collaborators — Eqology, NHL Select (Nordic), MycotechPharma, and Smartfish — each labeled as part of the integrated health solutions provider network. This structure is consistent with a model in which ImmunoPharma contributes research expertise or branding to consumer health products distributed by larger Nordic partners, rather than selling directly to end customers. No management team, revenue figures, funding history, patents, certifications, regulatory filings, marketing channels, or distribution channels are disclosed, leaving material gaps on capitalization, IP defensibility, and actual go-to-market mechanics.
ImmunoPharma AS firmographics
Firmographics- Name
- ImmunoPharma AS
- Legal name
- ImmunoPharma AS
- Website
- https://immunopharma.net
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- ImmunoPharma AS is a privately-held, 12-person Norwegian research company that targets immune stimulating substances and operates as an integrated health solutions provider through partnerships with Eqology, NHL Select (Nordic), MycotechPharma, and Smartfish.
- Ownership category
- akta.pro rank
ImmunoPharma AS industry classification
Industry- Product category
- Pharmaceutical Research & Immune Health
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
Keywords
Where ImmunoPharma AS is headquartered
LocationHeadquarters
- HQ city
- Oslo
- HQ country
- Norway
- HQ region
- Europe
Offices1 record
Markets served
ImmunoPharma AS business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
ImmunoPharma AS product offering
Product offeringCore offering
ImmunoPharma AS is a research-based pharmaceutical company that targets immune stimulating substances, positioning itself as an innovative integrated health solutions provider. The company coordinates a network of partner brands (Eqology, NHL Select Nordic, MycotechPharma, Smartfish) to deliver immune-health-focused solutions to Nordic markets.
Product overview
ImmunoPharma AS is a research-based pharmaceutical company targeting immune stimulating substances. The company operates as an integrated health solutions provider. No specific named products, modules, or distinct service offerings were identified in the available source material.
Differentiator
Problem solved
Functional benefit
Products and services
- Integrated health solutions (research-based) ImmunoPharma AS's own description refers to an 'innovative integrated health solutions provider' role built around research into immune stimulating substances, coordinated with partner brands. No discrete, named, sellable products, SKUs, or contracted service offerings were identified in the source material.
Companies that use ImmunoPharma AS
Customer profileIdeal customer profiles1 record
ImmunoPharma AS technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
ImmunoPharma AS partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- EqologycoreEqology appears as a strategic partner within ImmunoPharma's integrated health solutions network. The partnership is displayed prominently on the company website, indicating a collaborative relationship in providing comprehensive health solutions.
- NHL Select (Nordic)coreNHL Select (Nordic) is featured as a partner within ImmunoPharma's integrated health solutions ecosystem, suggesting collaboration in the Nordic health market.
- MycotechPharmacoreMycotechPharma is listed as a partner, indicating collaboration within the integrated health solutions network. The partnership suggests expertise sharing in mycological/pharmaceutical research.
- SmartfishcoreSmartfish is displayed as a partner in the integrated health solutions provider network, suggesting collaboration in health product development and distribution.
Recent moves4 records
Expansion highlights2 records
ImmunoPharma AS competitors and assessment
Company assessmentEmerging players
- ArcticZymes Technologies: Norwegian biotech developing enzyme and protein technologies for life sciences, including immune-related applications. Comparable as a small Nordic life sciences company with a research-based positioning.
- Circio Holding: Norwegian biotech developing circular RNA-based immune oncology and vaccines. Comparable as a Nordic emerging player in immune-stimulating therapeutics with overlapping geographic and scientific adjacency.
Broad incumbents
- Chr. Hansen (now Novonesis): Global bioscience company with a strong probiotic and immune health ingredient portfolio. Comparable as a broad incumbent commercializing microbial-based immune health products on a global scale.
- Thermo Fisher Scientific: Global life sciences tools and pharmaceuticals services company with broad immune health and vaccine adjuvants capabilities. Comparable as a broad incumbent in the immune health value chain.
- Bavarian Nordic: Danish established vaccine biopharmaceutical company with a broad infectious disease and immune-oncology portfolio. Comparable as a larger Nordic incumbent operating in immune-stimulating vaccines and immunotherapies.
- Lonza Group: Swiss global contract manufacturer for biologics and pharmaceuticals, including for immune-stimulating products. Comparable as a broad incumbent serving the immune health and biological product manufacturing ecosystem.
Direct peers
- Nykode Therapeutics (formerly Vaccibody): Norwegian clinical-stage biopharmaceutical company developing immune-stimulating vaccines and immunotherapies. Directly comparable as a Norway-based player focused on immune-stimulating therapeutic platforms.
- BioGaia: Swedish probiotics and immune health company with commercial probiotic strains targeting immune and gut health. Comparable to ImmunoPharma as a Nordic-based research-driven company commercializing immune-related health solutions through partner/distributor channels.
- Eurocine Vaccines: Swedish nasal vaccine immunology company developing immune-stimulating nasal vaccines. Comparable Nordic peer focused on immune stimulation and vaccine adjuvants.
Others
- Recipharm: Swedish pharmaceutical contract development and manufacturing organization. Comparable as a Nordic pharma services provider that could serve as a development/manufacturing partner for ImmunoPharma's research pipeline.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat2 records
Key risks6 records
Key highlights4 records
Customer concentration
ImmunoPharma AS social profiles
Digital presenceImmunoPharma AS financial estimates
Financial estimateRevenue estimate
Valuation estimate
ImmunoPharma AS leadership team
Management profileNumber of profiles
Profiles1 record
ImmunoPharma AS funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ImmunoPharma AS M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ImmunoPharma AS
What does ImmunoPharma AS do?
ImmunoPharma AS is a research-based pharmaceutical company that targets immune stimulating substances, positioning itself as an innovative integrated health solutions provider. The company coordinates a network of partner brands (Eqology, NHL Select Nordic, MycotechPharma, Smartfish) to deliver immune-health-focused solutions to Nordic markets.
Is ImmunoPharma AS a public or private company?
ImmunoPharma AS is a private company. It is classified as unknown and is currently operating.
When was ImmunoPharma AS founded?
ImmunoPharma AS was founded in -1. It employs 11 to 50 people.
Where is ImmunoPharma AS based?
ImmunoPharma AS is headquartered in Oslo, Norway, in the Europe region.
Who are ImmunoPharma AS's main competitors?
Emerging players on record are ArcticZymes Technologies and Circio Holding. Broad incumbents are Chr. Hansen (now Novonesis), Thermo Fisher Scientific, Bavarian Nordic and Lonza Group. Direct peers are Nykode Therapeutics (formerly Vaccibody), BioGaia and Eurocine Vaccines. Recipharm is listed as an others.
Does ImmunoPharma AS have an API?
No public API is recorded for ImmunoPharma AS.
What industry is ImmunoPharma AS in?
ImmunoPharma AS's product category is Pharmaceutical Research & Immune Health. Its primary akta.pro industry code is HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.